Advancing combination therapy for Alzheimer's disease

The study of Alzheimer's disease (AD) has led to an increased understanding of the multiple pathologies and pathways of the disease. As such, it has been proposed that AD and its various stages might be most effectively treated with a combination approach rather than a single therapy; however,...

Descripción completa

Detalles Bibliográficos
Autores principales: Salloway, Stephen P., Sevingy, Jeff, Budur, Kumar, Pederson, Jan Torleif, DeMattos, Ronald B., Von Rosenstiel, Philipp, Paez, Antonio, Evans, Rebecca, Weber, Christopher J., Hendrix, James A., Worley, Susan, Bain, Lisa J., Carrillo, Maria C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539671/
https://www.ncbi.nlm.nih.gov/pubmed/33043108
http://dx.doi.org/10.1002/trc2.12073
Descripción
Sumario:The study of Alzheimer's disease (AD) has led to an increased understanding of the multiple pathologies and pathways of the disease. As such, it has been proposed that AD and its various stages might be most effectively treated with a combination approach rather than a single therapy; however, combination approaches present many challenges that include limitations of non‐clinical models, complexity of clinical trial design, and unclear regulatory requirements. The Alzheimer's Association Research Roundtable meeting on May 7–8, 2018, discussed the approaches and challenges of combination therapy for AD. Experts in the field (academia, industry, and government) provided perspectives that may help establish a path forward for the development of new combination therapies.

Ejemplares similares